The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Open accessPublished version of a preprint
Abstract
Purpose: PD-1/PD-L1 signaling promotes tumor growth while inhibiting effector cell–mediated antitumor immune responses. Here, we assessed the impact of single and dual blockade of PD-1/PD-L1, alone or in combination with lenalidomide, on accessory and immune cell function as well as multiple myeloma cell growth in the bone marrow (BM) milieu. Experimental Design: Surface expression of PD-1 on immune effector cells, and PD-L1 expression on CD138+ multiple myeloma cells and myeloid-derived suppressor cells (MDSC) were determined in BM from newly diagnosed (ND) multiple myeloma and relapsed/refractory (RR) multiple myeloma versus healthy donor (HD). We defined the impact of single and dual blockade of PD-1/PD-L1, alone and with lenalidomide, on autologous anti–multiple myeloma immune response and tumor cell growth. Results: Both ND and RR patient multiple myeloma cells have increased PD-L1 mRNA and surface expression compared with HD. There is also a significant increase in PD-1 expression on effector cells in multiple myeloma. Importantly, PD-1/PD-L1 blockade abrogates BM stromal cell (BMSC)-induced multiple myeloma growth, and combined blockade of PD-1/PD-L1 with lenalidomide further inhibits BMSC-induced tumor growth. These effects are associated with induction of intracellular expression of IFNγ and granzyme B in effector cells. Importantly, PD-L1 expression in multiple myeloma is higher on MDSC than on antigen-presenting cells, and PD-1/PD-L1 blockade inhibits MDSC-mediated multiple myeloma growth. Finally, lenalidomide with PD-1/PD-L1 blockade inhibits MDSC-mediated immune suppression. Conclusions: Our data therefore demonstrate that checkpoint signaling plays an important role in providing the tumor-promoting, immune-suppressive microenvironment in multiple myeloma, and that PD-1/PD-L1 blockade induces anti–multiple myeloma immune response that can be enhanced by lenalidomide, providing the framework for clinical evaluation of combination therapy. Clin Cancer Res; 21(20); 4607–18. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, many studies have been conducted on cell lines and animal models in this context and have shown that blocking the PD 1/PD L1 axis in multiple myeloma has potential therapeutic effects [203–206].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [204]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although single-agent activity was limited, combining pembrolizumab with lenalidomide or pomalidomide and dexamethasone showed efficacy in single-arm trials. However, these combinations were associated with severe hematological and infectious toxicities, as well as immune-related adverse events such as pneumonia, hypothyroidism, adrenal insufficiency, hepatitis, and vitiligo. These adverse events”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [179]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, in a study by Görgün et al., they investigated the effect of lenalidomide on the PD 1/PD L1 pathway and finally found that blocking this pathway induced an anti-MM immune response that could also be enhanced by lenalidomide [204].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [204]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“As a result, infections remain a major cause of death (28).”
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“(28) Recent studies have defined immune checkpoint receptor PD1/PD-L1 signaling as a key pathway regulating the critical balance between immune activation and tolerance.(23, 28-31) Binding of PD1 on effector cells to PD-L1 or PD-L2 on non-hematopoietic cells triggers inhibitory signaling in effector cells, leading to…”
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392 · cited 1×
“(8, 15, 16, 20, 35, 37-40) Moreover, blockade of PD1/PDL1 signaling using clinically-relevant anti-PD1 monoclonal antibodies restored immune responses and achieved remarkable clinical responses in solid tumors including melanoma and lung cancer, providing a very promising novel immunotherapeutic strategy.”
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256 · cited 2×
“(28) Recent studies have defined immune checkpoint receptor PD1/PD-L1 signaling as a key pathway regulating the critical balance between immune activation and tolerance.(23, 28-31) Binding of PD1 on effector cells to PD-L1 or PD-L2 on non-hematopoietic cells triggers inhibitory signaling in effector cells, leading to…”
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203 · cited 2×
“cell lymphomas, chronic lymphocytic leukemia, acute myeloid leukemia, and multiple myeloma.(24, 25, 33, 41-45) In the present study, we investigated the role of PD1/PDL1 inhibitory signaling in the bidirectional interaction between tumor, stroma, and immune accessory cells in the MM BM microenvironment.”
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Cited by
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Tai, Y.-T., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 350
Self-citationT cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Zelle-Rieser, C., Thangavadivel, S., Biedermann, R., Brunner, A., Stoitzner, P., Willenbacher, E., Greil, R., & Jöhrer, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0345-3 · Cited by 319
“This is in accordance with recently published data [15, 24].”
BackgroundResultInfluentialImmunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Li, J., Stagg, N. J., Johnston, J., Harris, M. J., Menzies, S. A., DiCara, D., Clark, V., Hristopoulos, M., Cook, R., Slaga, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.001 · Cited by 296
“PD-L1 is frequently expressed by myeloma cells (Gorgun et al., 2015), and the signaling axis may limit T cell activity in myeloma patients.”
Background
Metadata
- Authors
- Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., Kikuchi, S., Harada, T., Hideshima, T., Tai, Y.-T., Laubach, J. P., Raje, N., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., Munshi, N. C., Dorfman, D. M., Richardson, P. G., & Anderson, K. C.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Centre National de la Recherche Scientifique (FR)
- 4Inserm UMR892, CNRS 6299, Université de Nantes, Nantes, France.
- 6Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France.
- Brigham and Women's Hospital (US)
- Corresponding author
- Görgün, Güllü
- Anderson, Kenneth C.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2015-10-14
- Volume
- 21
- Issue
- 20
- Pages
- 4607-4618
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4609232
- OpenAlex
- W1955732360
- Cited by
- 309
- References
- 53
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 17 · 2023: 21 · 2022: 26 · 2021: 35 · 2020: 41 · 2019: 25 · 2018: 45 · 2017: 41 · 2016: 28 · 2015: 6
- FWCI
- 31.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institutes of Health (5p01ca078378-15)
- National Cancer Institute (R01CA166480, P01-CA-78378, R01- CA50947, P01-CA078378, P50CA100707, R01CA050947)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- lenalidomide, PD-1/PD-L1 blockade, multiple myeloma, immune checkpoint blockade, myeloid-derived suppressor cells, mesenchymal stem cells, tumor microenvironment, immunosuppression, interferon-gamma, granzyme B, combination immunotherapy, relapsed/refractory multiple myeloma
- MeSH terms
- Lenalidomide, Antibodies, Monoclonal, Antigen-Presenting Cells, Bone Marrow, Humans, Interferon-gamma, Multiple Myeloma, RNA, Messenger, Thalidomide, Signal Transduction, Cell Line, Tumor, Cell Proliferation, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0200
- The paper
- Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., Kikuchi, S., Harada, T., Hideshima, T., Tai, Y.-T., Laubach, J. P., Raje, N., Magrangeas, F., Minvielle, S., Avet-Loiseau, H., . . . Anderson, K. C. (2015). Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.